Tech Transfer eNews Blog
University-Industry Engagement Advisor

Expert Strategies for Patenting and Licensing Early-Stage Drug Discoveries

By Jesse Schwartz
Published: October 13th, 2021

Universities are devoting tens of millions of research dollars toward drug discovery activity with no sign of a slowdown, and biopharma companies are increasingly relying on academia to fill their pipelines. Some universities have established their own drug development programs to de-risk their innovations and take them further toward commercialization, but for most schools the cost and risk involved is too high, and the development timeline is too long.

The most common commercialization approach is to file a patent application on an early-stage compound or drug candidate, claiming the novel and inventive aspects of the discovery, and then seek to license the early-stage asset to a commercial partner for further development.

Though it’s the more common pathway for universities and their TTOs, it’s far from a routine exercise, and rushing the process can be detrimental — if not catastrophic. Without a firm understanding of the criteria for patentability, essential claims language, data requirements, and how sponsored research and research partnerships come into play, your entire investment and your researchers’ years of hard work could go up in the smoke of invalidity challenges or licensee disinterest.

That’s why Tech Transfer Central’s Distance Learning Division is teaming up with Lisa Mueller, a patent attorney with deep experience in biopharma patent law and licensing, for this critically important webinar: Expert Strategies for Patenting and Licensing Early-Stage Drug Discoveries, scheduled for November 9th. Ms. Mueller will explore in detail patent strategies in academic drug discovery. Specifically, the criteria for patentability, including the patenting of salts, solvates, polymorphs and prodrugs as well as drug repurposing.

For complete program details or to register, click here.

Also coming soon:

Posted under: Distance Learning, Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment